Read more
Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.
The book is a valuable source for cancer researchers, oncologists and other members of the medical and biomedical field who are interested in learning more about recent developments in liquid biopsy and its relationship with precision medicine and immunotherapy.
List of contents
1. What is precision medicine in oncology?2. Liquid biopsy: a right tool in a right context?3. Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology4. Current clinically validated applications of liquid biopsy5. Liquid biopsy and immunotherapy: is all that glitter gold?6. Which technology performs better? From sample volume to extraction and molecular profiling7. Early detection screening: myth or reality?8. Molecular tumor board9. Future perspectives
About the author
Antonio Russo, MD, is a Full Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He is President of COMU (the Italian National Board of University Medical Oncologists), Italy. He is author of more than 350 publications in peer-reviewed journals. He focused his studies on liquid biopsy since 2003.Ettore Capoluongo, PhD, is a Full Professor of Clinical Biochemistry and Clinical Molecular Biology and, Head of Clinical Pathology Dept. Cannizzaro Hospital, Catania (Italy). He has published over 270 publications in peer-reviewed journals.Antonio Galvano, MD, PhD is an Associate Professor of Medical Oncology at DICHIRONS Dept, University of Palermo (Italy). He has focused his research efforts on liquid biopsies for cancer prognosis and treatment.Antonio Giordano, MD, PhD, is the Director at the Sbarro Institute at Temple University, Philadelphia (USA) and a Full Professor at University of Siena, Italy. He is best known for his discovery of cyclins, CDK9, CDK10 and Rb2/p130. He is the president and founder of the Sbarro Health Research Organization (SHRO), Philadelphia (USA). He has published over 600 publications in peer-reviewed journals.
